News | CT Angiography (CTA) | December 28, 2017

BlueCross BlueShield Companies in Eight States Issue Positive Medical Policies for HeartFlow FFRct Analysis

More than 90 million Americans now have non-invasive technology available as a medical benefit through commercial payers

BlueCross BlueShield Companies in Eight States Issue Positive Medical Policies for HeartFlow FFRct Analysis

December 28, 2017 — HeartFlow Inc. announced that Health Care Service Corp. (HCSC), which operates Blue Cross and Blue Shield plans in five states, has issued a medical policy for the HeartFlow FFRct Analysis, a non-invasive technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD). HCSC — which operates Blue Cross Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma and Texas — has determined that the use of noninvasive fractional flow reserve (FFR) following a positive coronary computed tomography (CT) angiogram may be considered medically necessary to guide decisions about the use of invasive coronary angiography in patients with stable chest pain at intermediate risk of CAD.

Additionally, BlueCross BlueShield companies in Tennessee, Louisiana and South Carolina recently issued a positive medical policy for the HeartFlow FFRct Analysis. After reviewing the technical performance, diagnostic accuracy, clinical utility and clinical benefits, all three entities concluded that the use of the HeartFlow FFRct Analysis following a coronary CT angiogram may be considered medically necessary for its members with stable chest pain and results in meaningful improvements in the net health outcome.

HCSC plans collectively cover nearly 15 million members across five states. BCBS of Tennessee covers 3.4 million members, Blue Cross and Blue Shield of Louisiana covers 1.6 million members, and BCBS of South Carolina covers approximately 850,000 people in the state.

The Centers for Medicare & Medicaid Services (CMS) and a growing number of commercial payers and professional organizations have recognized the value of the HeartFlow FFRct Analysis in diagnosing patients with suspected CAD, according to the company. CMS finalized a New Technology Ambulatory Payment Classification (APC) for the HeartFlow FFRct Analysis in November. Beginning Jan. 1, 2018, hospitals that are enrolled in Medicare and bill CMS will be able to submit claims for the HeartFlow FFRct Analysis for Medicare patients.

In addition to the new private payers, Anthem, Aetna and several other Blue Cross Blue Shield companies recently have issued positive medical coverage decisions. Evidence Street, which conducts healthcare technology evaluations for the Blue Cross Blue Shield Association, a national federation of 36 independent Blue Cross and Blue Shield companies, issued a positive review. In the U.K., the National Institute for Health and Care Excellence (NICE) of the National Health Service, which covers 64.6 million lives, also issued positive guidance. The American College of Cardiology (ACC) and American Heart Association (AHA) released updated Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart Disease. These criteria include the use of HeartFlow FFRct Analysis in determining the appropriateness of revascularization in many clinical scenarios.

For more information:

Related Content

Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis

Philips to Develop FFR-Angiography in Partnership With HeartFlow

VIDEO: Early U.S. Experience With FFR-CT in Evaluating ED Chest Pain Presentation

Related Content

Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening
News | Lung Cancer | August 15, 2018
August 15, 2018 — Although national guidelines advise doctors to discuss the benefits and harms of...
Videos | Magnetic Resonance Imaging (MRI) | August 13, 2018
Haojie Wang, M.D., director of advanced cardiovascular MRI and a member of the heart valve clinic at Baylor Scott Whi
ACR LI-RADS Steering Committee Releases New Version of CT/MRI LI-RADS
News | Clinical Decision Support | August 13, 2018
August 13, 2018 — The American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) steering commit
Aidoc Receives FDA Clearance for AI Detection of Acute Intracranial Hemorrhage
Technology | Clinical Decision Support | August 08, 2018
Aidoc announced that it was granted U.S. Food and Drug Administration (FDA) clearance for the first product of its...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Varian Showcases Advanced Cancer Care Solutions at AAPM 2018
News | Radiation Therapy | July 27, 2018
Varian announced it will be showcasing its advanced cancer care solutions, including a new version of the Eclipse...
Videos | Computed Tomography (CT) | July 25, 2018
A discussion with Patricia Dickson, LRT(CT), director of imaging and outpatient services, Capital Cardiology Associat
computed tomography brain scan

Image courtesy of Pixabay

News | Clinical Trials | July 19, 2018
The use of computed tomography (CT) scans has increased dramatically over the last two decades. CT scans greatly...
CT Decision Instrument Reliably Guides Pediatric Blunt Trauma imaging Decisions

This is a four-site prospective observational cohort. Image courtesy of Kirsty Challen, B.Sc., MBCHB, MRES, Ph.D., Lancashire Teaching Hospitals, United Kingdom.

News | Clinical Decision Support | July 18, 2018
A new study finds The Pediatric NEXUS Head Computed Tomography (CT) Decision Instrument (DI) reliably identifies blunt...
Overlay Init